Showing results (301-310 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|March 15, 2020
Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccinationZiena Abdulrahman, Noel de Miranda, Edith M G van Esch, et al.Journal for Immunotherapy of Cancer|December 12, 2018
Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansionLinsen Ye, Qi Zhang, Yusheng Cheng, et al.Journal for Immunotherapy of Cancer|January 17, 2019
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapyAurelie Hanoteau, Jared M Newton, Rosemarie Krupar, et al.Journal for Immunotherapy of Cancer|November 30, 2019
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCCAliya Qayyum, Ken-Pin Hwang, Jason Stafford, et al.Journal for Immunotherapy of Cancer|October 31, 2019
Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypesO I Isaeva, G V Sharonov, E O Serebrovskaya, et al.Journal for Immunotherapy of Cancer|November 2, 2019
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete responseFlorence Baettig, Tatjana Vlajnic, Marcus Vetter, et al.Journal for Immunotherapy of Cancer|January 16, 2020
NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinomaRahul Suresh, David J Barakat, Theresa Barberi, et al.Journal for Immunotherapy of Cancer|February 9, 2020
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular diseaseEsther Lutgens, Tom T P SeijkensJournal for Immunotherapy of Cancer|February 9, 2020
High-dimensional immune-profiling in cancer: implications for immunotherapySamuel Chuah, Valerie ChewJournal for Immunotherapy of Cancer|February 12, 2020
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse modelsTaiki Kurino, Reiko Matsuda, Ayu Terui, et al.Pageof 424